Vertex CMO sells 1,974 shares under 10b5-1 plan

Vertex Pharmaceuticals executive Carmen Bozic reported an open-market sale of 1,974 shares of Common Stock at $450.00 per share.

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Carmen Bozic reported an open-market sale of 1,974 shares of Common Stock at $450.00 per share. The transaction left her with 22,760 shares held directly. According to the disclosure, the sale was made under a pre-arranged Rule 10b5-1 trading plan entered into on 11/20/2025, indicating it was scheduled in advance rather than timed discretionarily.

Insights

Insider trading and governance analyst

Pre-planned, modest insider sale with significant remaining holdings.

Executive vice president and CMO Carmen Bozic sold 1,974 shares of Vertex Pharmaceuticals Common Stock at $450.00 per share in an open-market transaction. After the sale, she continues to hold 22,760 shares directly, indicating she retains a meaningful equity position.

The filing specifies that this sale was executed under a company-approved Rule 10b5-1 trading plan entered into on 11/20/2025. Such plans schedule trades in advance and reduce the informational value of transaction timing, framing this as routine portfolio management rather than a discretionary shift in outlook.

Insider Trade Summary 10b5-1

Net Seller: 1,974 shares

Net Sell 1 txn

Insider Bozic Carmen

Role EVP and CMO

Sold 1,974 shs ($888K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,974	$450.00	$888K

Holdings After Transaction: Common Stock — 22,760 shares (Direct)

Footnotes (1)

1. F1. Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025.

Key Figures

Shares sold: 1,974 shares Sale price: $450.00 per share Shares held after transaction: 22,760 shares +2 more

5 metrics

Shares sold 1,974 shares Open-market sale of Common Stock

Sale price $450.00 per share Price for the 1,974-share sale

Shares held after transaction 22,760 shares Direct holdings following sale

Plan entry date 11/20/2025 Date Rule 10b5-1 trading plan was entered

Transactions reported 1 sale Non-derivative open-market transaction

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vertex (VRTX) executive Carmen Bozic do in this Form 4?

Carmen Bozic sold 1,974 shares of Vertex Common Stock in an open-market transaction at $450.00 per share. The trade was reported on Form 4 and reflects a planned disposition rather than a new purchase of shares.

At what price did Carmen Bozic sell Vertex (VRTX) shares?

She sold the 1,974 Vertex shares at $450.00 per share in an open-market transaction. This per-share price is explicitly disclosed and is the only price reported for this sale in the filing.

How many Vertex (VRTX) shares does Carmen Bozic hold after this transaction?

After the reported sale, Carmen Bozic directly holds 22,760 shares of Vertex Common Stock. This post-transaction share count is provided in the Form 4 as the total shares beneficially owned following the sale.

Was the Carmen Bozic sale of Vertex (VRTX) shares under a Rule 10b5-1 plan?

Yes. The filing notes the sale was made pursuant to a company-approved Rule 10b5-1 trading plan. That plan was entered into on 11/20/2025, indicating the transaction was pre-scheduled rather than timed based on short-term market developments.

Is this Vertex (VRTX) Form 4 a buy or sell transaction?

This Form 4 reports a sell transaction. It shows an open-market sale of 1,974 shares of Vertex Common Stock by executive Carmen Bozic, with no corresponding share purchases, option exercises, or grants disclosed in this particular filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 04:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bozic Carmen

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and CMO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		S(1)		1,974	D	$450	22,760	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)